stringent. The more stringent a multiple testing correction, the less false-positive genes are allowed. The trade-off of a stringent multiple testing correction is that the rate of false negatives is very high. To reduce false negatives, P values were not corrected. This may be debatable but is done in practice (3, 4) . Furthermore, the association remained significant after the Bonferroni correction for AKT1: rs2494732 (i.e., <0.05/16 ¼ 0.003) in our study. Otherwise, AKT1:rs2498804 and rs2494732 were in strong linkage disequilibrium (D ¼ 0.95), and we believe that AKT1: rs2498804 is not a false-positive gene (1) . In addition, we are pleased to find that the association of AKT1:rs2498804 was confirmed in your independent cohorts. We think that this is a very good method to avoid false positives.
Giovannetti and colleagues also raised concerns about the treatment details in our study. We agree with them on this issue. In fact, we have described that the treatment details included surgery, chemotherapy, and radiotherapy. Unfortunately, we have no information on EGFR mutation status or ALK translocations, so we are unable to address this important comment. However, we can report early findings from an ongoing study of 70 patients receiving oral erlotinib in a program supported by the China Charity Federation. The results were the same as those in our study ( Table 2 ). The data have been provided in our response to the reviewers. Finally, we admit that there are limitations with our study and agree with Giovannetti and colleagues that further research is needed to unravel the functional significance of these polymorphisms. We are currently using immunohistochemistry to detect AKT protein expression in NSCLC primary tissues, and additional functional validation is ongoing.
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